Mobble
Health · Drug development · published 2026-08-27 · via Endpoints News

Moderna raises $2B, while partners report Phase 3 successes

Moderna is offering convertible senior notes to raise $2 billion, aiming to fund its oncology expansion and repay debt. Separately, AstraZeneca and Amgen, along with Biokin, announced positive Phase 3 trial results. Additional updates include news from Takeda China and ProFound.

Read the full article at Endpoints News →
Related stories
AstraZeneca reports positive late-stage results for two lung cancer therapies · Cancer research
Ivonescimab meets key goal in biliary tract cancer trial, partners report · Cancer research
AstraZeneca terminates Phase 3 volrustomig study following lung cancer failure · Cancer research
Amgen ends TScan partnership, Amylyx unveils $350M financing · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source. Original headline: “Moderna's $2B offering; AstraZeneca-Amgen and Biokin chalk up Phase 3 wins.” Browse more stories.